The Agreement includes an investment of $1.2 million and distribution of GLFIs products to ST Biosciences International Customers

LAS VEGAS, NV / ACCESSWIRE / August 18th, 2020 / GLFI, Inc., doing business as Green Leaf Farms International a privately held company that is a majority owned subsidiary of Players Network, Inc. (OTC PINK:PNTV), which has been established to finance and manage international cannabis operations outside North America and has its first operation in Jujuy Argentina, announced today that it has entered into a joint venture agreement with ST Biosciences to fund, in part the company's initial 35 hector (86 acre) Pilot Project.

ST Biosciences, a vertically integrated company, with operations in 31 countries specializes in the development of plant-based medicine, the development of GMP and EMP extraction labs, and global supply chain distribution to companies worldwide.

The Joint Venture includes an initial $1.2 million dollar investment in exchange for a 30% stake in GLFI's portion of the Pilot Project plus certain distribution rights to purchase the company's cannabis derived flower and oils for exportation to ST Biosciences existing global customers. The Company believes this agreement will result in revenues and profits to the joint venture. The investment will allow GLFI to compete its infrastructure of greenhouses, outdoor cultivation to support the initial pilot project to the point of revenue. ST Bioscences also as an option to invest in the company's planned expansion in Jujuy.

Jason Frankovich ST Biosciences CEO states " it is crucial to establish international sales and distribution of pharmaceutical grade cannabis for this industry to strive. The relationship with Green Leaf Farms International and ST helps solidify a distribution platform that services over 5 different counties in South America".

Mark Bradley CEO of GLFI states" This is the perfect partnership GLFI has been seeking for the last year. It will bring the experience in developing pharmaceutical grade cannabis oils and worldwide distribution in the exporting of cannabis derived products to our project. This combined with our 12-month growing season and low production cost is expected to allow us to compete with any market in the world". Bradley adds, "The two companies' synergies are tremendous. ST Biosciences CEO, Jason Frankovich, is a true pioneer and has been a pleasure to work with. We look forward to a long future together with this being just the first project.

About GLFI, Inc.

GLFI, Inc. (Green Leaf Farms International) is a privately held subsidiary of PNTV.PK established to finance and manage international cannabis operations. Its first project is 86 acres of cannabis cultivation located in Jujuy, Argentina. GLFI will not hold any US cannabis-related assets this will enable institutional investors to participate in the legal cannabis and CBD industries. To learn more about opportunities with GLFI, please visit our website; www.GLFI.co.

Instagram: https://www.instagram.com/greenleaffarmsjujuy/

Facebook: https://www.facebook.com/greenleaffarmsjujuy

For more information please visit https://glfi.co

About Player's Network (PNTV.PK)

Players Network is a publicly traded corporation celebrating its 30th year as a media company whose primary business is focused in television and video production, delivery platforms, network development, and new media technology, platforms, and content. The Company subsequently created, developed, and launched a broadband network, "Weed TV". The company has invested into Green Leaf Farms for the management of a HEMP and Cannabis business in North Las Vegas and Green Leaf Farms International, Inc for the development of those businesses outside the United States.

Information about Forward-Looking Statements

This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: inability to gain or maintain licenses, reliance on unaudited statements, the Company's need for additional funding, governmental regulation of the cannabis industry, the impact of competitive products and pricing, the demand for the Company's products, and other risks. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

For Inquires:

Investor relations
David Berry
702-374-1771
Email. dberry@playersnetwork.com

SOURCE: GLFI, Inc.

ReleaseID: 601964

Nature Consulting Inc. Has Revenues Of $7.4 Million Through June 2020 Since Founding In February 2019

HOLLYWOOD, FL / ACCESSWIRE / August 18, 2020 / Thunder Energies Corporation (OTC PINK:TNRG), on August 14, 2020, filed an 8K with the Securities and Exchange Commission (SEC) outlining its recent reverse acquisition agreement of a private company, Nature Consulting, Inc. As a result of the related transactions, the business of Natural Consulting, LLC became Thunder Energies Corp.'s main operation. Natural Consulting, LLC is the premier source of turnkey CBD and Hemp extract solutions, providing high quality products and comprehensive services for its clients. The company was founded in February 2019 and as of June 2020 the Company had over $7.4 million in total sales to date. The Company had sales in excess of $2.2 million is 2019 which has grown to $5.2 million during 2020 through June, reflecting that CBD sales have continued to rise despite the global pandemic.

The Company specializes in hemp extract manufacturing and distribution, with over 15 years of combined experience in the cannabis industry and a network of over 1,000 premium U.S. CBD and hemp brands suppliers. Over the past two years the Company has become one of the nation's leading suppliers of quality CBD products and the USA's premiere source for turnkey white and private label hemp extract product solutions.

According to the 8K, on August 14, 2020 (the "Closing Date"), Thunder Energies Corp and the members of Natural Consulting, LLC entered into an Interest Purchase Agreement (the "Interest Purchase Agreement"), which closed on the same date. Pursuant to the terms of the Interest Purchase Agreement, the members of Natural Consulting, LLC sold all of their membership interest in Natural Consulting, LLC to Thunder Energies Corp in exchange for sixty million (60,000,000) shares of Thunder Energies Corp's Common Stock. As a result of this transaction, Natural Consulting, LLC became a wholly-owned subsidiary of Thunder Energies Corp.

Previously, on July 1, 2020, Yogev Shvo, an individual and principal shareholder of Nature Consulting, LLC., a Florida limited liability company, (the "Purchaser") personally acquired 100% of the issued and outstanding shares of preferred stock (the "Preferred Stock") of Thunder Energies Corporation, a Florida corporation, from Saveene Corporation, a Florida corporation (the "Seller"). The purchase price of $250,000.00 for the Preferred Stock was paid in cash. The consideration for the purchase was provided to the Purchaser from the individual private funds of Yogev Shvo.

After the Interest Purchase Agreement Mr. Shvo will assume the position of Chairman with Mr. Adam Levy serving as CEO/President. Ms. Gloria Galindez will be the CFO with accounting and finance responsibilities. Mr. Levy and Ms. Galindez will jointly supervise the Company's operations. Direct Reports will be Mr. Edwin Paredes (Production Manager), Ms. Michaela Steward (Head of Design Department) and Mr. Keon Dunbar (Sales Manager).

The membership Interest Purchase Agreement will be treated as an asset acquisition by the Company for financial accounting purposes. Thunder Energies Corp will be considered the acquirer for accounting purposes, and the historical financial statements of Natural Consulting, LLC, before the membership exchange will replace the historical financial statements of Thunder Energies Corp. before the membership exchange and in all future filings with the SEC.

The issuance of shares of the Company's Common Stock to members of Natural Consulting, LLC in connection with the Interest Purchase Agreement was not registered under the Securities Act, in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act, which exempts transactions by an issuer not involving any public offering, and Regulation D and/or Regulation S promulgated by the SEC under that section. These securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement, and are subject to further contractual restrictions on transfer as described below.

The parties also agreed not to register under the Securities Act the resale of the shares of the Company's Common Stock received in the Share Exchange by its officers, directors and key employees and holders of 10% or more of our Common Stock for a period of two years following the closing of the Share Exchange.

To view a full copy of the filing go to: https://sec.report/Document/0001683168-20-002756/#a1

The Company plans to file for a new trading symbol and for a name change and also plans to upgrade to the OTCQB in the near future.

About Nature Consulting, Inc.
Nature Consulting, Inc. based in Miami, Florida, is one of the nation's leading suppliers of top-quality CBD products and the U.S. premier source for turnkey white and private label hemp extract product solutions. Its mission is to be the leading seed-to-sale manufacturer and supplier of high-quality CBD products in the industry. Nature Consulting features superior quality products, reliable industry certifications, and a more scalable, diverse range of services than the competition. Its subsidiary, The Hemp Plug, is an innovative leader for quality extraction and sourcing, expert brand building, and targeted marketing for retailers and wholesalers throughout the world. They provide a range of scalable services for building CBD brands, from customization to order fulfillment to brand development and label design. The Company has the largest inventory of organic, non-GMO hemp and CBD products on the market. It enables third parties to enter into the growing CBD market, acting as a vertical incubator from seed to store shelves… from wholesale to internet to brick and mortar sales via its omnichannel strategy which maintains the growth of our customer base using creativity paired with the most advanced marketing tools, technology, and brand events. It provides its customers with Products, Website, Landing Pages, Digital Marketing, Social Media, White Paper and other Events marketing services. For more information about the Company please go to: http://thehemplug.com/

Forward-Looking Statements:
This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. That includes the possibility that the business outlined in this press release cannot be concluded for some reason. That could be as a result of problems that were not anticipated. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Nature Consulting, Inc. to be materially different from the statements made herein. Except for any obligation under the U.S. federal securities laws, Nature Consulting, Inc. undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

CONTACT:
Company Address:
3017 Greene Street
Hollywood, Florida 33020
Telephone: (786) 686-0231

For All Inquiries Contact:
Email: info@natureconsulting.com

SOURCE: Thunder Energies

ReleaseID: 602065

WEST MELBOURNE, FL / ACCESSWIRE / August 18, 2020 / BK Technologies Corporation (NYSE American:BKTI) today announced that its operating subsidiary received an order totaling approximately $1.1 million dollars from the National Interagency Fire Center (NIFC). The order is for BK's KNG2-Series Digital P-25 portable radios with related accessories. This order is anticipated to be fulfilled during the third quarter of 2020.

BK President Tim Vitou commented, "As we have for so many years, BK is proud to support NIFC and the professional wildland firefighting community. They have relied upon our products in wildland fire suppression efforts for over two decades; first deploying our E-Series and G-Series analog radios, then our P-25 D-Series radios, and more recently migrating to our KNG2 P-25 digital radios. BK's extended track record of dependability in harsh and life-threatening conditions has clearly earned the NIFC's confidence as demonstrated by this recent order."

BK's KNG2-Series P25 public safety grade radios have been a cornerstone for tactical communications in the wildland firefighting community for over 10 years. The proven design has been enhanced with the features and functionality needed by firefighters for command and control operations. Ease of use, long battery life, loud clear audio and features such as radio-to-radio in- the-field programming, also known as cloning, makes the KNG2-Series the industry leader in the wildland fire suppression vertical market. https://www.bktechnologies.com/product/kng2-portable-radio/

About BK Technologies

BK Technologies Corporation is an American holding company deeply rooted in the public safety communications industry, with its operating subsidiary manufacturing high-specification communications equipment of unsurpassed reliability and value for use by public safety professionals and government agencies. BK Technologies is honored to serve these heroes with reliable equipment when every moment counts. The Company's common stock trades on the NYSE American market under the symbol "BKTI". Maintaining its headquarters in West Melbourne, Florida, BK Technologies can be contacted through its web site at www.bktechnologies.com or directly at 1-800-821-2900.

Forward-Looking Statements

This press release contains certain forward-looking statements that are made pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements concern the Company's operations, economic performance and financial condition and are based largely on the Company's beliefs and expectations. These statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks, some of which have been, and may further be, exacerbated by the COVID-19 pandemic, include, among others, the following: changes or advances in technology; the success of our land mobile radio product line; successful introduction of new products and technologies, including our ability to successfully develop and sell our anticipated new multiband product and other related products in the planned new BKR Series product line; competition in the land mobile radio industry; general economic and business conditions, including federal, state and local government budget deficits and spending limitations, any impact from a prolonged shutdown of the U.S. Government, and the ongoing effects of the COVID-19 pandemic; the availability, terms and deployment of capital; reliance on contract manufacturers and suppliers; risks associated with fixed-price contracts; heavy reliance on sales to agencies of the U.S. Government and our ability to comply with the requirements of contracts, laws and regulations related to such sales; allocations by government agencies among multiple approved suppliers under existing agreements; our ability to comply with U.S. tax laws and utilize deferred tax assets; our ability to attract and retain executive officers, skilled workers and key personnel; our ability to manage our growth; our ability to identify potential candidates for, and consummate, acquisition, disposition or investment transactions, and risks incumbent to being a noncontrolling interest stockholder in a corporation; impact of our capital allocation strategy; risks related to maintaining our brand and reputation; impact of government regulation; rising health care costs; our business with manufacturers located in other countries, including changes in the U.S. Government and foreign governments' trade and tariff policies, as well as any further impact resulting from the COVID-19 pandemic; our inventory and debt levels; protection of our intellectual property rights; fluctuation in our operating results and stock price; acts of war or terrorism, natural disasters and other catastrophic events, such as the COVID-19 pandemic; any infringement claims; data security breaches, cyber-attacks and other factors impacting our technology systems; availability of adequate insurance coverage; maintenance of our NYSE American listing; risks related to being a holding company; and the effect on our stock price and ability to raise equity capital of future sales of shares of our common stock. Certain of these factors and risks, as well as other risks and uncertainties, are stated in more detail in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in the Company's subsequent filings with the SEC. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements.

Company Contact:

Hayden IR
James Carbonara
james@haydenir.com
(646)-755-7412

SOURCE: BK Technologies Corporation

ReleaseID: 602056

The bamboos market is highly fragmented, with numerous small-scale, regional players. Government aid will be critical for the survival of these businesses through the coronavirus crisis

DUBAI, UAE / ACCESSWIRE / August 18, 2020 / The global bamboos market is projected to display strong growth between 2019 and 2029, to reach an estimated valuation of US$ 12 billion. On the other hand, the industry is likely to be strongly affected in the short term, largely owing to lockdown restrictions imposed on nations around the world which has impacted supplies of fresh bamboo to end use industries. The market is expected to display gradual recovery owing to economic uncertainty arising from the outbreak.

"Applications in the textile and furnishings industry are key contributors to revenue in the bamboos market. Environmental and sustainability awareness among consumers have been major influencers. Use in food as an immune boosting ingredient has gained traction during the coronavirus pandemic creating opportunities for market players," states the FMI analyst.

To know more about this market, request a sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-347

Bamboos Market- Critical Takeaways

Paper and pulp applications for bamboo material has increased substantially with growing importance being given to sustainability initiatives in the sector.
Consumption of food and nutraceutical products comprising bamboo has increased, driven by high nutrition and low-calorie formulation profiles.
Asia Pacific remains the leading market for bamboos, driven by large-scale cultivation and exports, in addition to favorable government policies towards the industry.

Bamboos Market- Drivers

Niche application in the infrastructure construction sector as sustainable building material increases demand for bamboo.
Major contributions from the bamboo industry towards job generation and environmental efforts has generated favor among consumers and governments.

Bamboos Market- Restraints

Applications of potentially toxic chemicals in bamboo processing operations, and associated regulations hinder market growth.
Extinction of bamboo species has been a major area of concern for market players.

Coronavirus Impact on Bamboos Market

The global bamboos industry has had to face significant challenges during the coronavirus pandemic. Lack of adequate fresh bamboo supplies, owing to transport and logistical disruptions from lockdowns has hurt market prospects. Lower disposable incomes have reduced demand from bamboo product consumers. Furthers, shut down of food service businesses has also hurt demand for edible bamboo. Financial support for small scale players from governments will be essential to their survival.

For information on the Research Approach used in the Report, Request Methodology@ https://www.futuremarketinsights.com/askus/rep-gb-347

Competitive Landscape

EcoPlanet Bamboo, Moso International B.V., Bamboo Village Co. Ltd., Bamboo Australia Pvt. Ltd., and Shanghai Tenbro Bamboo Textile Co. Ltd. are some of the leading participants in the bamboos market.

Players in the Bamboos market have been found to expand operations geographically through strategic acquisitions and through government collaborations to consolidate supply and distribution networks.

For instance, EcoPlanet Bamboo has announced the expansion of its operations into South Africa, with the acquisition of SA Bamboo. Further, Heijinghe Biotechnology Co., Ltd has opened a new bamboo shoot processing plant in collaboration with the government in China's Zhenxiong County. Also, the government of Assam in India has announced the development of a Bamboo Industrial Park, which will open to market players in 2021.

For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-347

About the Study

The study offers readers an assessment of the bamboos market. Global, regional and national-level analysis of the latest trends influencing the bamboos market is covered in this FMI report. The study provides insights according to end use industry (wood & furniture, construction, food, pulp & paper, textile, agriculture, and others) in four regions (North America, Latin America, Asia Pacific, and Europe, Middle East & Africa).

Explore FMI's Coverage of the Chemicals & Materials Industry

Biobased Biodegradable Plastics Market– Get insights on the global biobased biodegradable plastics market through FMI's report covering quantitative and qualitative analysis for projection period 2014-2020.

BRIC Automotive Plastics Market– FMI's exhaustive study on the BRIC automotive plastics market covers the latest trends, innovations, key players, and popular strategies for the period 2015-2020.

Bio-Plastics Market– Obtain detailed analysis on the bio-plastics market through FMI's report covering competitive analysis, key regions, and segmental analysis for 2014-2020.

About Future Market Insights

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FMI helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the chemicals & materials sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.

Contact

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Report: https://www.futuremarketinsights.com/reports/bamboos-market
Press Release Source: https://www.futuremarketinsights.com/press-release/bamboos-market

SOURCE: Future Market Insights

ReleaseID: 602204

Company Plans to File Second Quarter 2020 Report before the end of August

FT. LAUDERDALE, FL / ACCESSWIRE / August 18, 2020 / PotNetwork Holdings, Inc. (OTC PINK:POTN) ("the Company") announced today that the Company has filed its First Quarter 2020 Report with the Securities and Exchange Commission ("SEC").

Kevin Hagen, President, CEO and a Director of the Company, stated, "We are pleased to announce that the Company has now filed its First Quarter 2020 Report on form 10-Q with the SEC. Sales for the period of January through March exceeded $2,000,000. Despite the current COVID-19 pandemic situation, sales in the second quarter have remained steady and have been building. By month's end, we plan to file our Second Quarter 2020 Report for the period of April through June, at which point the Company will then be up-to-date with its SEC filings." He added, "Today, we are continuing to refine and refresh our extensive product line and expect sales in 2020 to build month-over-month to a strong finish."

About PotNetwork Holdings, Inc.: PotNetwork Holdings, Inc. (OTC Pink: POTN) is a publicly traded SEC reporting company that acts as a holding company for its principal subsidiaries, First Capital Venture Co., the owner of Diamond CBD, Inc., the maker of Diamond CBD products, and PotNetwork Media Group, Inc., the publisher of PotNetwork News and PotNetwork Magazine. For more information, please visit, www.potnetworkholding.com.

As an SEC reporting company, the Company's financial statements for calendar years 2017, 2018 and 2019 are fully audited. All the Company's public SEC filings are readily accessible on the SEC's Edgar website under "PotNetwork Holdings, Inc."

About Diamond CBD, Inc.: Diamond CBD focuses on the research, development, and multinational marketing of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. Diamond CBD's team consists of hemp industry pioneers and natural product experts, chemists, doctors and scientists, dedicated to producing the finest and purest cannabidiol (CBD) oils. The result is a robust selection considered among the most powerful natural CBD oils, tinctures, edibles, vape liquids and other CBD containing products found anywhere. For more information, please visit its website at www.DiamondCBD.com.

Safe Harbor: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

PotNetwork Holdings, Inc.
1-800-915-3060
investor@PotNetworkHolding.com

SOURCE: PotNetwork Holdings, Inc.

ReleaseID: 602135

Significant advancement achieved with ARDS-003 sterile injectable nano-emulsion finished drug product

A new anti-inflammatory drug candidate

OTTAWA, ON / ACCESSWIRE / August 18, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has awarded the contract for the manufacturing of its active pharmaceutical ingredient (API), HU-308, and of the intravenous, sterile, finished drug product ARDS-003 to Dalton Pharma Services (Dalton).

HU-308 is a synthetic small molecule new chemical entity which specifically targets the human CB2 receptors and has the potential to be a new anti-inflammatory drug. Dalton has developed and improved the synthesis process for HU-308. In preparation for moving the clinical program forward, additional activities are underway which include manufacturing drug batches of HU-308 and ARDS-003. This allowed Tetra to carry out the nonclinical safety program and studies required to generate the data needed for a clinical trial application in both Canada and the USA. The development of a GMP batch manufacturing process is ongoing along with a first scale-up to fulfill Tetra's clinical requirements. To-date, the drug specifications and analytical quality control methods for the release of both the API and injectable formulation are completed and in the final validation stage. The placebo and active injectable formulations have been developed using FDA approved excipients for intravenous emulsions which will avoid additional toxicology testing to qualify the non-medicinal ingredients. The first injectable product batches were shown to have adequate particle size for sterile filtering and filter compatibility. Sterile filtering is the optimal method for obtaining a sterile injectable drug.

"Dalton is pleased to be working with Tetra on this important new drug to potentially treat cytokine release syndromes. Dalton will play an important role in the development of this innovative drug and we look forward to a long and productive partnership with Tetra," said Peter Pekos, CEO, Dalton Pharma Services.

Dr. Guy Chamberland, CEO and CRO commented, "We are very pleased to be working with Dalton on this high priority project to bring ARDS-003 into clinical trials. This partnership was ideal for Tetra as Dalton recognized the urgency and proposed a plan that aligns with our corporate objective to bring this investigational drug into clinical trials as soon as possible. More importantly, this plan ensured that all aspects of the regulatory requirements and GMP compliance were respected. As a pharmaceutical company, the progress achieved at this point, and within such an accelerated timeframe is significant in that we can now attest that ARDS-003 conforms to the standard quality and compatibility requirements of other injectable prescription drugs for human use".

About Dalton

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved and FDA registered cGMP contract service provider of integrated chemistry, drug development and manufacturing services to the pharmaceutical and biotechnology industries. Dalton brings over 30 years of experience to their client's projects and emphasizes quality, speed and flexibility. Dalton can accelerate a drug development program by integrating drug discovery, formulation and process development, custom synthesis, cGMP sterile fill/finish of liquids and powders, cGMP API manufacturing and/or dosage form manufacturing and Accelerated Stability Testing, all at a single location that helps Dalton to be adaptable, flexible and cost-effective.

For Dalton's full range of in-house services including cGMP sterile fill/finish services please visit www.dalton.com

CMO 2016, 2017 and 2018 Leadership Awards in the categories of Quality, Reliability, Capabilities, Expertise, Compatibility and Development from Life Science Leader reflects Dalton's ongoing commitment to their clients, peers and the business community. In 2017 Dalton was re-certified as "A Great Place to Work."

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF), is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.:

Investor Contact:

Tetra Bio-Pharma Inc
Dr. Guy Chamberland, M.Sc., Ph.D.
Chief Executive Officer
Phone: 1 (833) 977-7575
investors@tetrabiopharma.com

Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (646) 255-0433
tetra@alphabronze.net

Media Contact:

energi PR
Ms. Carol Levine APR, FCPRS
Phone: + 1 (416) 425-9143 ext. 226
Mobile: + 1 (514) 703-0256
carol.levine@energipr.com

SOURCE: Tetra Bio-Pharma

ReleaseID: 602152

JACKSON CENTER, PA / ACCESSWIRE / August 18, 2020 / Halberd Corp. (OTC PINK:HALB) Chairman, President & CEO of Halberd Corporation, William A. Hartman, has received a number of questions from shareholders regarding the extracorporeal process for treatment of Covid-19. Below, Mr. Hartman responds to those questions.

Q: There are various extracorporeal medical procedures being researched or used and in various states of trial and approval. How do these differ from your patented process?

A: All extracorporeal processes have one thing in common – they all consist of removing something from the blood, or cerebral spinal fluid, while the bodily fluid is outside the patient. The difference is in how the offending substances – target disease antigens – are removed before the bodily fluid is returned to the body. Some methods use conventional mechanical filtration, others use chemical attraction, or other means to attract and trap the target antigens and remove them. Our patents, and pending patents, have unique features to the technology that are distinguishable from other extracorporeal processes which we believe gives us a technological edge and precludes others from pursuing a similar path.

Regardless of which extracorporeal process is employed, they all differ from conventional medical treatments in that conventional treatments involve adding something to the patient – drugs or chemicals administered through an IV, intramuscular injection, orally, trans-nasally or through inhalation. Extracorporeal treatments remove things from the patient – the disease antigens. This is the revolutionary aspect of our intended treatment.

Q: How does the extracorporeal process work?

A: Overall, the process is very similar to standard kidney dialysis. Blood is removed from the patient, and is pumped through a cartridge containing and retaining complexing molecules designed to attract the particular targeted disease antigen. After passing through the cartridge, the blood is returned to the patient, while the target antigens stay in the antigen cartridge. The process includes monitoring the concentrations of the target antigens in the incoming, pre-filtered blood, and also the cleansed blood returning to the patient as a key indicator of effectiveness of the "filtration" process.

Q: What are complexing agents?

A: Complexing agents are simply molecules that demonstrate a strong affinity for the target antigens. When these antigens are exposed to its corresponding designed complexing agent, they are attracted to, and sequestered by it, thereby enabling them to be removed from the blood. These complexing agents are permanently affixed to the interior surfaces of the cartridge for removal and disposal at the completion of the extracorporeal treatment. Since the capture and removal process is one of a molecular bond, it is a bit different than a normal mechanical filter which traps and removes particles based on their physical size. The attraction and capture of the antigens can be thought of like a magnet and iron filings.

Q: Can you elaborate a bit on these complexing agents? Are they broad in scope, like a magnet attracting all different grades of iron, or specific, targeting a single, specific antigen?

A: That depends on what you are looking to eliminate from the blood, or cerebral spinal fluid (CSF). We've only discussed here the application of the process to the blood, but it is equally applicable to CSF for diseases associated with spinal fluid.

There are a couple of ways of attacking a disease: you can remove the disease antigen directly, or remove one or more of the elements the disease needs to survive. So you can remove the antigen itself, or you can starve it to death. But this is not an either/or proposition. You can do both simultaneously. It just depends on the design intent is of the complexing agent(s) used in the treatment cartridge – single or multiple targets.

Our recent provisional patent application, Method for Treating and Curing Covid-19 Infection, addresses targeting the entire Covid-19 molecule – single target, while the provisional patent application, Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients, uniquely seeks a simultaneous removal of multiple targets related to elements which support the cytokine storm present in later-stage Covid-19 cases.

In this way, we believe we can selectively remove various disease causing agents from the blood or CSF depending on the design of the complexing agents – or "magnets" to use that analogy – used in the cartridge, without putting any drugs or chemicals into the patient. This greatly reduces or eliminated the chances of adverse reactions to the treatment. The process removes the toxic elements from the blood without disturbing the rest of the body.

This is distinctly different than a vaccine which often has the capacity of causing harm and in some cases more harm than good. And many people reject vaccination. Often our treatment may be the only alternative for people.

Q: You mentioned in earlier press releases about an extracorporeal process that uses a laser to eliminate the disease antigens. How does that work?

A: It works much the same way as described above, but instead of a complexing agent that attracts and holds it to the interior surfaces of a cartridge, it "lights up" the target antigen using a fluorescent chemical. Instead of a cartridge, a laser targeting area is created to enable the antigen-fluorescent conjugate pair to pass through the laser's focal area. At that stage they are detected by the nano laser targeting system and eliminated with a burst of controlled energy from the nano laser. The nano laser is highly focused, and controlled, to eliminate any collateral damage to surrounding cells.

Q: Where do you get the complexing agents for use in your treatment process?

A: That is where our partnership with one or more research universities comes in. Halberd's scientists have identified antigen targets we believe need to be removed from the blood in order to rid the body of Covid-19. We will be directing one or more of our university partner(s) to develop agents that will selectively attract and capture the target antigens. These complexing agents will then need to be permanently attached to the inner surfaces of the filtration cartridge and then tested for safety and efficacy. These are the first steps in a development sequence that we believe could lead to a technique to remove any number of viruses from the human body and could ultimately revolutionize medicine.

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133

Twitter:@HalberdC

About Halberd Corporation.
HalberdCorporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Title

Application No.

Filing Date

Priority

Status

Method for Treating and Curing Covid-19 Infection

US 62/989981

03/16/2020

n/a

Provisional application Pending

Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients

US 63/007207

04/08/2020

n/a

Provisional application Pending

Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus

US 63/013104

4/21/2020

n/a

Provisional application Pending

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

ReleaseID: 602148

KINGSTON, ON / ACCESSWIRE / August 18, 2020 / Delta Resources Limited ("Delta" or "The Company") (TSXV:DLTA)(OTC PINK:GOLHF)(FRA:6G01) is pleased to report that its ongoing mechanical trenching program at the Delta-2 property in Chibougamau, Quebec has uncovered a sulphide-bearing horizon favourable for the presence of Volcanogenic Massive Sulphide (VMS) mineralization.

The favourable horizon coincides with a string of isolated VTEM conductors that represent VMS targets. The target horizon is characterized by the presence of felsic tuffaceous sediments, sulphide-bearing chert, sulphidic iron formation and volcanic rocks of rhyolitic affinity (see photos attached), believed to represent a pause in the volcanic sequence. Sulphide mineralization is typically dominated by pyrite and pyrrhotite with chalcopyrite and sphalerite in minor amounts (1-5%). No graphite has been observed on the conductive horizon, ruling out a graphitic source for the VTEM conductors. To date, this favourable horizon can be followed for over five kilometres along strike.

André Tessier, President and CEO at Delta commented as follows:

"Uncovering this favourable horizon is a significant step forward for our VMS exploration program at Delta-2. Not only does it confirm our geological model but it reaffirms the potential of the VTEM conductors along the horizon. The presence of sphalerite and chalcopyrite are also of great importance, indicating the right mineralizing processes are present for the formation of economic deposits."

Mechanical trenching was carried out to expose bedrock to surface following the field-proofing of electro-magnetic conductors deemed to be excellent targets for VMS polymetallic mineralization of the same type as the past producing Lemoine Mine which is located 1.5 kilometre north of the property. Between 1975 and 1983, the extraordinarily rich Lemoine Mine produced 757,585 tonnes of ore grading 9.52% Zn, 4.18% Cu, 4.56 g/t Au and 82.26 g/t Ag (Source: www.sigeom.mines.gouv.qc.ca).

The Delta-2 project is located 35 kilometres southeast of the town of Chibougamau and now covers over 156 square kilometres. Targets at the Delta-2 project consist of VMS mineralization similar to the Lemoine Mine which is located 1.5 kilometre north of the property.  In addition, Delta is also targeting magmatic-hydrothermal gold deposits related to the La Dauversiere pluton, such as the Joe Mann past producer (1956-2007: 1.173 million ounces of gold at a grade of 8.26 g/t Au, 607,000 ounces of silver at 5 g/t Ag and 28.7 million pounds of copper at 0.25% Cu) (Source: Technical Report on the Joe Mann Mining Property dated January 11, 2016, prepared by Geologica Inc.).

Chert Horizon with disseminated pyrrhotite-sphalerite and chalcopyrite.

Sulphide-bearing felsic tuffaceous rocks at the contact between mafic volcanic flows.

Sulphide-bearing felsic tuffs (in red) at the contact between rhyolites and mafic volcanics.

Qualified Person

Andre C. Tessier, P.Eng and P.Geo. President and CEO of Delta Resources Limited is a Qualified Persons as defined by NI-43-101 and is responsible for the technical information presented in this press release.

About Delta Resources Limited

Delta Resources Limited is a Canadian mineral exploration company focused on growing shareholder value through the acquisition of high-potential gold and base-metal projects in Canada, exploring these projects with state-of-the-art methods, and potentially developing these projects into mines.

Delta is currently exploring its Eureka Gold Discovery in the Thunder Bay area (Delta-1) and its Delta-2 Gold-Polymetallic Property in the Chibougamau Mining District of Quebec.

Delta also owns a 100% interest in the Bellechasse-Timmins gold deposit in southeastern Quebec. On July 3rd, 2020, Delta announced the sale of the Bellechasse-Timmins project.

The Company continues to focus on building upon its strong portfolio of mineral exploration properties with a high potential for economic discoveries in Canada.

ON BEHALF OF THE BOARD OF DELTA RESOURCES LIMITED.

Andre C. Tessier
President, CEO and Director
www.deltaresources.ca

We seek safe harbor. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has not approved nor disapproved of the information contained herein.

For Further Information:

Delta Resources Limited
Andre C. Tessier, CEO and President
Tel: 613-328-1581
atessier@deltaresources.ca

or

Frank Candido, Chairman
Tel : 514-969-5530
fcandido@deltaresources.ca

Cautionary Note Regarding Forward Looking Information

Some statements contained in this news release are "forward looking information" within the meaning of Canadian securities laws. Forward looking information include, but are not limited to, statements regarding the use of proceeds of the non-brokered private placement and payment of the debt settlements. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases (including negative or grammatical variations) or statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative connotation thereof. Investors are cautioned that forward-looking information is inherently uncertain and involves risks, assumptions and uncertainties that could cause actual facts to differ materially. There can be no assurance that future developments affecting the Company will be those anticipated by management. The forward-looking information contained in this press release constitutes management's current estimates, as of the date of this press release, with respect to the matters covered thereby. We expect that these estimates will change as new information is received. While we may elect to update these estimates at any time, we do not undertake to update any estimate at any particular time or in response to any particular event.

SOURCE: Delta Resources Limited

ReleaseID: 602155

Compact tractor manufacturers are transitioning rapidly towards smart factory facilities and setting up localized supply chains to minimize the damage accrued during the ongoing pandemic.

ROCKVILLE, MD / ACCESSWIRE / August 18, 2020 / The compact tractors market is estimated to cross a valuation of US$ 4.2 Bn through the period of forecasting between 2020 and 2030. The coronavirus pandemic however, is expected to restrain short term growth prospects in the compact tractors market. Disruptions in international supply chains and drop in dealership sales are likely to hurt market players. In addition, applications in construction sectors have also gone down. However, leasing businesses are likely to pick up pace, influencing market developments.

"Compact tractors are relatively affordable to conventional tractor models. Such farming equipment has achieved popularity due to low-weight, reduced fuel costs, and minimal damage to crops during operations, all of which will sustain sales through the assessment period," says the Fact.MR report.

Request a sample of the report to gain more market insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=3940

Compact Tractors Market – Key Takeaways

20 to 40 hp tractors are witnessing increased sales, driven by interest for affordable mechanization from small and medium size farming businesses.
Diesel powered compact tractors remain dominant, owing to lack of adequate electricity infrastructure in rural areas in developing economies.
Asia Pacific remains a major market for compact tractors owing to growing labor costs and major importance of agrarian markets in national economies of the region, such as Australia, India, and China.

Compact Tractors Market – Driving Factors

Investments into product development for multi-functional compact tractors, with harvesting, puddling, reaping, and hauling capabilities is boosting sales prospects.
Rising migration of farm workers to urban areas, and the resultant shortage of labor resources contribute to sales.

Compact Tractors Market – Constraints

Despite relative affordability of compact tractors, cost remains a major obstacle to sales, particularly in low-income farming communities in developing economies.
Tariffs imposed by governments on international trade of compact tractors and components is holding back market growth.

Anticipated Market Impact by Coronavirus Outbreak

The coronavirus pandemic has severely impacted international supply chains in the compact tractors sector. Also, the outbreak has reduced sales in dealerships, owing to lower disposable incomes among rural communities. Further, health concerns for factory workers has restricted operations in the manufacturing sector. On the other hand, market players are finding potential growth opportunities through virtual marketing and customer service resources, investments into precision agriculture, factory automation, and localization of supply and distribution networks.

Explore the global compact tractors market with 124 figures, 70 data tables, along with the table of contents of the report. You can also find detailed segmentation on https://www.factmr.com/report/3940/compact-tractor-market

Competition Landscape

Major manufacturers in the compact tractors market include but are not limited to Yanmar Co. Ltd., Deere & Co., LS Mtron, AGCO Corp., Argo Tractors S.p.A, Mahindra & Mahindra Ltd., Escorts Ltd., CNH Industrial N.V., Daedong Industrial Co. Ltd., and Tong Yang Moolsan.

Leading players in the compact tractors market are pushing for the expansion of product portfolios with launches of new offerings in multiple specifications to meet custom needs of end users.

For instance, John Deere has announced the release of 13 compact tractor models between 25 to 66 hp for 2020. Kubota Canada Ltd. has unveiled a new series of 3 open station and cab compact tractor models for commercial operations. Similarly, Bobcat Company has introduced 15 new compact tractor models ranging from 21 to 58 hp.

More on the Report

The FACT.MR's market research report provides in-depth insights on compact tractors market. The market is scrutinized according to power (less than 20 hp, 21 to 30 hp, 31 to 40 hp, 41 to 50 hp, and less than 60 hp), transmission (hydrostatic and mechanical), and application (mowing, agriculture, snow clearing, landscaping and others) across six key regions (North America, Latin America, Europe, East Asia, South Asia & Oceania, and Middle East and Africa).

Explore Wide-ranging Coverage of FACT.MR's Automotive Landscape

Tractors Market: Find insights on the global tractors market with analysis of segments, statistics, influencers, market players and business strategies adopted over a 9-year forecast period.

Aircraft Tow Tractors Market: FACT.MR's report on the aircraft tow tractors market offers insights on the market during 2018-2028, including restraints, revenue sources, market leaders, and market strategies.

Electric Tractors Market: Read an analysis on the electric tractors market with insights on growth factors, opportunities, restraints, regional market forecast, regulatory policies, and strengths of market leaders.

About Fact.MR

Fact.MR is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Fact.MR is headquartered in Dublin, Ireland, and has delivery centers in the U.S. and India. FACT.MR's latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1578/global-compact-tractor-market

SOURCE: FactMR

ReleaseID: 602206

Ceramic tile manufacturers are displaying increasing concern towards the application of eco-friendly materials and manufacturing processes to keep up with changing sustainability trends.

DUBAI, UAE / ACCESSWIRE / August 18, 2020 / The ceramic tiles market is anticipated to reach a massive valuation of US$ 120 billion in 2020, displaying promising growth prospects through 2030. However, the market is expected to go through a short-term downturn during the coronavirus pandemic, owing to major disruptions in supplies and stoppage or reduction of construction sector activities, owing to lockdown regulations.

"Governments are increasingly investing in low cost homes development projects, which is expected to bolster growth for the duration of the forecast period. Further, the changing consumer bias towards ceramic tiles in terms of aesthetics is a prominent factor projected to bolster demand in the long-term," states the FMI analyst.

Download a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-1669

Ceramic Tiles Market- Critical Takeaways

Flooring applications of ceramic tiles continue to account for major revenue share supported by availability of wide-ranging aesthetic and textural options.
Non-residential applications are rising at a rapid pace, supported by growing scope of decorative applications in commercial spaces.
Asia Pacific is expected to reflect strong production and consumption of ceramic tiles, aided by easy availability of raw materials and growing investments into renovation activities.

Ceramic Tiles Market- Drivers

Major government investments into public recreation spaces and utility infrastructure drives demand for ceramic tiles.
Transition towards smart cities with multi-story residential buildings is generating lucrative opportunities.

Ceramic Tiles Market- Restraints

Growing concerns about the environmental impact of producing ceramic tiles restrains market growth.
Ceramic tiles are more prone to cracking to impact, which limits adoption rates.

We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-1669

Coronavirus Impact on Ceramic Tiles Market

Nationwide lockdowns imposed by governments around the world during the coronavirus crisis has restrained activity in the construction industry. This in turn, is expected to adversely impact the ceramic tiles industry through 2020. The lockdowns have also restricted operations in the clay mining industry which is essential for ceramic tile production. However, with gradual relaxation on construction activities towards the end of the year, prospects for ceramic tile sales is likely to witness steady recovery. Maintaining inventory and competitive pricing are key strategies during the crisis period.

Competitive Landscape

China Ceramics Co. Ltd., RAK Ceramics, Kajaria Ceramics, Crossville Inc., Mohawk Industries, Atlas Concorde, Gruppo Ceramiche Ricchetti, Saloni Ceramica, Florida Tile, and Porcelanosa Grupo are some of the leading players in the ceramic tiles market.

Manufacturers in the ceramic tiles market are increasingly displaying interest in pricing strategies and material and production process innovations with concerns to aesthetics to widen their portfolios.

For instance, Grespania has unveiled its patina collection of ceramic tiles developed to reflect metallic motifs. Roca Tile has released its Rockart collection of bespoke shape tiles to allow for a wider range of floor and wall layouts. Further, Natucer has revealed its customized D'autore ceramic tiles range which includes 3D textures such as bevels and ridges.

Request Special Price for this Report to our Sales Executive@ https://www.futuremarketinsights.com/request-special-price/rep-gb-1669

About the Study

The study offers readers a comprehensive assessment of the Ceramic tiles market. Global, regional and national-level analysis of the latest trends influencing the ceramic tiles market is covered in this FMI report. The study provides insights according to product (floor, wall and others), and application (residential replacement, new residential, commercial, and others) in six regions (North America, Latin America, Europe, East Asia, South Asia & Pacific, and MEA).

Explore FMI's Coverage of the Chemicals & Materials Industry

Barite Market– Get insights on the global barite market through FMI's report covering detailed quantitative and qualitative analysis for projection period 2020-2030.

Adsorbents Market– FMI's exhaustive study on the adsorbents market covers the latest trends, innovations, key players, and popular strategies for the period 2017-2027.

Polyvinyl Chloride Market– Obtain detailed analysis on the polyvinyl chloride market through FMI's report covering competitive analysis, key regions, and segmental analysis.

About Future Market Insights

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FMI helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the chemicals and materials sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.

Contact:

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Report: https://www.futuremarketinsights.com/reports/ceramic-tiles-market
Press Release Source: https://www.futuremarketinsights.com/press-release/ceramic-tiles-market

SOURCE: Future Market Insights

ReleaseID: 602202